Ljubimov Lab
The Ljubimov lab is focused on developing gene, epigenetic and nano therapy for diabetic corneal disease, as well as novel blood-brain barrier-passing nanodrugs for brain tumor treatment. The emphasis is on drug action on stem cells. The lab employs state-of-the-art methods including nanopolymer development, gene expression analysis in single cells, and epigenetic modifier treatments.
Personal Statement
Dr. Ljubimov is Director of the Division of Applied Cell Biology and Physiology, Department of Biomedical Sciences, Director of Board of Governors Regenerative Medicine Institute Eye Program, Professor of Biomedical Sciences and Neurosurgery, and Professor of Medicine at UCLA. He is studying ocular diabetes for 30 years and developing nanodrugs for cancer.
Alexander Ljubimov, PhD
Breakthrough Research
Diabetic corneal disease is treated only symptomatically. The Ljubimov Lab has described new alterations in diabetic corneas and developed gene and epigenetic therapy to normalize corneal wound healing and stem cells. Combination nanotherapy for brain cancer directed at immune system and tumor microenvironment was designed and tested in mice.
Publications
Learn more about the recent research publications from the Ljubimov Lab.
Collaborations
The Ljubimov Lab collaborates with a wide range of investigators within Cedars-Sinai and institutions around the world.
- Grant Lab—University of Alabama, Birmingham
- Kopeček Lab—University of Utah, Salt Lake City
- Patil Lab—Loma Linda University, Loma Linda,
- Skottman Lab—University of Tampere